Treatment Algorithms for Systemic Sclerosis According to Experts

Arthritis and Rheumatology

Volumn 70, Issue 11, 2018, Pages 1820-1828

  Fernández Codina, Andreu ^a   Walker, Kyle M ^b   Pope, Janet E ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; DOXYCYCLINE; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; METOCLOPRAMIDE; METRONIDAZOLE; MYCOPHENOLATE MOFETIL; OCTREOTIDE; PHOSPHODIESTERASE V INHIBITOR; PREDNISONE; PROSTANOID; RIFAXIMIN; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; CALCIUM CHANNEL; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PROSTAGLANDIN;

ALGORITHM; ARTICLE; CLINICAL PRACTICE; DIASTOLIC DYSFUNCTION; FEMALE; FINGER ULCER; GASTROINTESTINAL DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL LUNG DISEASE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SCLERODERMA; SKIN DISEASE; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; ARTHRITIS; COMPLICATION; CONSENSUS DEVELOPMENT;

ALGORITHMS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS; CALCIUM CHANNELS; CYCLOPHOSPHAMIDE; ENDOTHELIN RECEPTOR ANTAGONISTS; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LUNG DISEASES, INTERSTITIAL; METHOTREXATE; MYCOPHENOLIC ACID; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; RAYNAUD DISEASE; RITUXIMAB; SCLERODERMA, SYSTEMIC;

EID: 85053440736     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40560     Document Type: Article

References (28)

1. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Prim 2015;1:15002.
2. Denton CP, Khanna D. Systemic sclerosis. Lancet (London) 2017;56:912–21.
3. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012;51:1017–26.
4. Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol 2017;69:1067–77.
5. Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Semin Arthritis Rheum 2017;46:767–74.
6. Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails–a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012;42:42–55.
7. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
8. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017;76:1897–905.
9. Lee JJ, Pope JE. Diagnosis and management of systemic sclerosis: a practical approach. Drugs 2016;76:203–13.
10. Khanna D, Distler JH, Sandner P, Distler O. Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord 2016;1:186–93.
11. Gordon JK, Domsic RT. Clinical trial design issues in systemic sclerosis: an update. Curr Rheumatol Rep 2016;18:38.
12. Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford) 2016;55:1906–10.
13. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327–39.
14. Pope JE, Ouimet JM, Krizova A. Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum 2006;55:138–45.
15. Harding S, Khimdas S, Bonner A, Baron M, Pope J, Canadian Scleroderma Research Group. Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG). Clin Exp Rheumatol 2012;30 Suppl 71:S38–43.
16. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007;66:940–4.
17. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017;76:1219–27.
18. Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017;76:422–6.
19. Shah RJ, Boin F. Lung transplantation in patients with systemic sclerosis. Curr Rheumatol Rep 2017;19:23.
20. Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA 2016;315:1975–88.
21. Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 2013;65:1460–71.
22. Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, et al. Mycophenolate mofetil versus placebo for systemic sclerosis–related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol 2017;69:1451–60.
23. Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017;46:625–31.
24. Khanna D, Denton CP, Lin CJ, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2017;387:2630–40.
25. Eyraud A, Scouppe L, Barnetche T, Forcade E, Lazaro E, Duffau P, et al. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature. Br J Dermatol 2018;178:650–8.
26. Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 2017;76:1207–18.
27. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018;378:35–47.
28. Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72:1217–20.